Insuman Comb 25

Insulin human (rDNA), the active ingredient in Insuman Comb 25, is an insulin presented as an injection solution for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in patients requiring insulin therapy.

GNH USA supplies Insuman Comb 25 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 25 is an insulin formulation used to manage blood glucose in diabetes mellitus and related hyperglycemic conditions. - Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target glycemic control. - Type 2 diabetes mellitus: used when oral agents are insufficient to maintain adequate glucose levels. - Diabetic ketoacidosis: administered as part of emergency insulin therapy to rapidly lower plasma glucose.

Insuman Comb 25 may cause a range of adverse reactions, most of which are related to its pharmacologic action or injection site.

Common Side Effects: - Hypoglycemia: symptomatic low blood glucose levels. - Weight gain: increase in body mass due to improved glucose utilization. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat. - Localized allergic reactions: mild rash or urticaria.

Serious or Rare Side Effects: - Severe hypoglycemia leading to seizures or loss of consciousness. - Anaphylactic reaction: systemic allergic response requiring emergency care. - Edema: fluid retention causing swelling of extremities. - Hypokalemia: low serum potassium levels, especially with high insulin doses.

When using Insuman Comb 25, careful monitoring and patient education are essential to minimize risks. - Monitor blood glucose regularly: adjust dose based on self‑monitoring results. - Adjust dose during illness or stress: hyperglycemia may require temporary dose increase. - Use caution in renal impairment: reduced clearance can enhance hypoglycemic risk. - Avoid use in patients with known hypersensitivity to insulin human or its excipients. - Pregnancy and lactation: consult a healthcare professional before initiating therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 25 can interact with several drug classes, affecting glycemic control or masking symptoms.

Major Interactions (Avoid): - Sulfonylureas: additive hypoglycemic effect may cause severe low blood glucose. - Beta‑blockers: may mask typical hypoglycemia warning signs such as tachycardia. - MAO inhibitors: potential for enhanced insulin action and hypoglycemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may increase insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can raise blood glucose, possibly necessitating higher insulin doses. - Oral contraceptives: hormonal changes may alter insulin requirements.